# US 10,494,607 B2 · CD34+,CD45−placental stem cell-enriched cell populations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,494,607 B2
- Document ID: US10494607B2
- Status: Granted
- Kind: B2
- Application number: 12/030,170
- Filed: 2008-02-12
- Published: 2008-08-28
- Granted: 2019-12-03
- Earliest claimed: 2007-02-12
- Assignees: Celularity Inc.
- Applicants: James W. Edinger; Robert J. Hariri; Jia-Lun Wang; Qian Ye; Marian Pereira; Sascha Dawn Abramson; Kristen S. Labazzo
- Inventors: James W. Edinger; Robert J. Hariri; Jia-Lun Wang; Qian Ye; Marian Pereira; Sascha Dawn Abramson; Kristen S. Labazzo
- Web page: https://patentgrep.com/patent/US10494607B2

## CPC

- C12N 5/067: {Hepatocytes}
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 19/00: Drugs for skeletal disorders
- A61P 31/12: Antivirals
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- C12N 5/0655: {Chondrocytes; Cartilage}
- A01K 2267/0337: Animal models for infectious diseases
- A61K 2035/128: {capsules, e.g. microcapsules}
- C12N 2500/30: Organic components
- C12N 2500/36: Lipids
- C12N 2500/62: DMSO
- C12N 2501/15: Transforming growth factor beta (TGF-β)
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N 2506/02: from embryonic cells
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2533/32: Polylysine, polyornithine
- C12N 2533/40: Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- C12N 2533/74: Alginate
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are methods and compositions for the production of hepatocytes from placenta stem cells. Further provided herein is the use of such hepatocytes in the treatment of, and intervention in, for example, trauma, inflammation, and degenerative disorders of the liver. Also provided herein are compositions and methods relating to combinations of nanofibrous scaffolds and adherent placental stem cells and methods of using the same in cartilage repair. Finally, provided herein are compositions and methods relating to nonadherent, CD34+CD45− stem cells from placenta.

## Claims

### Claim 1

A method of producing an isolated CD34+, CD45− hematopoietic placental stem cell population, comprising selecting CD34+ cells from a population of placental cells using antibodies to form a population of CD34+ placental cells, removing from said population of CD34+ placental cells CD45+ cells using antibodies, and combining the resulting cells with a physiologically-acceptable aqueous saline solution, wherein a CD34+, CD45− hematopoietic placental stem cell population is produced.

### Claim 2 (depends on 1)

The method of claim 1, wherein said population produces CFU-E or BFU-E when cultured in vitro.

### Claim 3 (depends on 1)

The method of claim 1, wherein at least 50% of cells in said population are CD34+, CD45−.

### Claim 4 (depends on 1)

The method of claim 1, wherein at least 70% of cells in said population are CD34+, CD45−.

### Claim 5 (depends on 1)

The method of claim 1, wherein at least 90% of cells in said population are CD34+, CD45−.